EVMN
EVMN
NYSE · Biotechnology

Evommune Inc

$23.33
-0.23 (-0.98%)
As of Mar 22, 10:20 PM ET ·
Financial Highlights (FY 2026)
Revenue
7.39M
Net Income
-70,586,400
Gross Margin
Profit Margin
-954.4%
Rev Growth
D/E Ratio
0.21
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 42.8% 42.8% 42.8%
Operating Margin -1,000.2% -23.9% -25.5% -21.7%
Profit Margin -954.4% -21.4% -26.9% -27.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 7.39M 78.02M 75.69M 85.24M
Gross Profit 33.42M 32.42M 36.51M
Operating Income -73,962,610 -18,680,583 -19,332,133 -18,489,345
Net Income -70,586,400 -16,723,517 -20,379,208 -23,619,828
Gross Margin 42.8% 42.8% 42.8%
Operating Margin -1,000.2% -23.9% -25.5% -21.7%
Profit Margin -954.4% -21.4% -26.9% -27.7%
Rev Growth -7.7% +21.3% +18.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 78.56M 82.29M 83.85M 90.36M
Total Equity 374.28M 243.06M 274.02M 233.46M
D/E Ratio 0.21 0.34 0.31 0.39
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -72,652,002 -28,105,243 -27,281,553 -29,215,509
Free Cash Flow -11,355,754 -12,035,038 -9,988,803